Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Vericel Corp. (VCEL)

Add VCEL Price Alert      Hide Sticky   Hide Intro
Moderator: lasers
Search This Board: 
Last Post: 6/21/2017 9:00:50 AM - Followers: 151 - Board type: Free - Posts Today: 0

Vericel Corporation. (VCEL)




Acquisition of Sanofi’s CTRM Business
On May 30, 2014, we completed the acquisition of the Cell Therapy and Regenerative Medicine (CTRM) business of Sanofi, a French  société anonyme  (Sanofi), certain assets, including all of the outstanding equity interests of Genzyme Biosurgery ApS (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over 250 patents and patent applications of Sanofi and certain of its subsidiaries, and assumed certain liabilities for purposes of acquiring the portion of the CTRM business, which researches, develops, manufactures, markets and sells Carticel, MACI and Epicel.
We believe that our acquired CTRM business has been a pioneer in the development and commercialization of autologous cell therapies. The CTRM portfolio includes three autologous cell therapy products: Carticel (autologous cultured chondrocytes), a first-generation product for autologous chondrocyte implantation (ACI) currently marketed in the U.S., Epicel (cultured epidermal autografts), a permanent skin replacement for full thickness burns in adults and pediatrics with greater than or equal to 30% of TBSA, also currently marketed in the U.S, and MACI (matrix-applied characterized autologous cultured chondrocytes), a third-generation ACI product approved in Europe and for which a Biologics License Application (BLA) is under review by the FDA. Our product candidate portfolio also includes ixmyelocel-T, a patient-specific multicellular therapy currently in development for the treatment of advanced heart failure due to ischemic DCM.




                                                                      Click on Yellow to REVIEW FDA WEBSITE APPROVING MACI


Interesting FDA Transcript discussions on MACI going forward for widened age bracket and other body joints. 
                                                                                                                                      CLICK ON THE ABOVE LINK



 Our preapproval stage portfolio includes ixmyelocel-T, a unique patient-specific multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. Our proprietary cell manufacturing process significantly expands the mesenchymal stromal cells (MSCs) and M2-like anti-inflammatory macrophages in the patient’s bone marrow mononuclear cells while retaining many of the hematopoietic cells. These cell types are known to regulate the immune response and play a key role in tissue repair and regeneration by resolving pathologic inflammation, promoting angiogenesis, and remodeling ischemic tissue. The novelty and advantage of using ixmyelocel-T is the expansion of a unique combination of cell populations, including MSCs and M2-like macrophages, which secrete a distinct combination of angiogenic and regenerative factors, and possess the ability to remain anti-inflammatory in the face of inflammatory challenge.

Our lead clinical development program for ixmyelocel-T is focused on severe, chronic ischemic cardiovascular diseases. We have completed the double-blind portion of the Phase 2b ixCELL-DCM study, which is a randomized, double-blind, placebo-controlled clinical trial for patients with advanced heart failure due to ischemic DCM. Ixmyelocel-T has been granted a U.S. Orphan Drug designation by the FDA for the treatment of DCM. We also have conducted clinical studies for the treatment of critical limb ischemia and the treatment of craniofacial defects.
The Phase 2b ixCELL-DCM clinical study treated 114 patients at 28 sites in the U.S. and Canada. We completed enrolling and treating patients in February, 2015. Patients were followed for 12 months for the primary efficacy endpoint of major adverse cardiovascular events, defined as all-cause deaths, all-cause hospitalizations, and unplanned outpatient or emergency department visits for IV treatment of acute worsening heart failure. Secondary endpoints include clinical, functional, structural, symptomatic, quality of life, and biomarker measures at 3, 6 and 9 months. On March 10, 2016, we announced the trial had met its primary endpoint of reduction in clinical cardiac events, and that the full data results from the ixCELL-DCM trial were presented at the Late-Breaking Clinical Trial Sessions of the American College of Cardiology 65 th Annual Scientific Session & Expo on April 4, 2016. On April 4, 2016, we announced that incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to or lower than patients in the placebo group.  With respect to the secondary endpoints of the trial, the components of the primary endpoint were also analyzed using the Win ratio in a hierarchical manner to incorporate both the incidence and timing of the endpoint components.  The Win ratio result of 1.56 showed that more often ixmyelocel-T was the "winner" in that the time to death, left ventricular assist device placement, heart transplantation or time to cardiovascular hospitalization was shorter for placebo-treated patients, but this difference did not reach statistical significance.  The time to first

Table of Contents
event was longer in the ixmyelocel-T group compared to placebo, but was not statistically significant.  There were no significant structural changes in left ventricle cavity size or left ventricular ejection fraction as measured by echocardiogram in either the ixmyelocel-T or placebo groups.  Both treatment groups had an improvement in the New York Heart Association class and six-minute walk test, with no statistical difference between the groups after 12 months using the last observation carried forward. Because the trial met the primary endpoint, patients who had been assigned to the placebo group or randomized to ixmyelocel-T in the double blind portion of the trial but did not receive ixmyelocel-T will be offered the option to receive treatment.
Future development plans for ixmyelocel-T are dependent upon input from our regulatory interactions and the availability of financing. We are focused on determining the most appropriate manner to fund future development of ixmyelocel-T, balancing risk to the overall business, dilution to current shareholders, and retaining a significant portion of the upside potential of the program for the company and our shareholders.

Ixmyelocel-T for Craniofacial Tissue Engineering

                           Click on above picture to enter another talk/idea zone


About Vericel Corporation:

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).

Developing autologous (patient’s own) cell therapies—with integrity
Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient’s own) cells.  In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work.  We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.

                                                                                               CLICK ON ABOVE PICTURE TO SEE NASDAQ.COM SHORT INTEREST

Clinical Research:
Recent News:

Events and Presentations:

Analyst Coverage:


Share Structure:
See Filings

YOU TUBE VIDEOS, and the fourth video down, you will NOW appreciate the meaning of less invasive on the new FDA approved MACI procedure and why MACI is anticipated to be 20x the procedures of Carticel  MUST WATCH

Conference Calls
September 27, 2016 Ladenburg Thalmann
October 24, 2016 Meeting on the Mesa
November 30th, 2016 The 28th Annual Piper Jaffray Healthcare Conference
December 14th, 2016 Vericel Corporation Investor Call

Investor Relations:




 Yummy Land, click on Above Picture


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#4674  Sticky Note The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in lasers 04/05/16 05:33:01 PM
#6210   COVERAGE INITIATED: Vericel (VCEL) initiated by BTIG Research. lasers 06/21/17 09:00:50 AM
#6209   $VCEL initiated with a new Buy and $6 realfast95 06/20/17 04:23:05 PM
#6208   Why VCEL is a sure thing to go commoncentsinvestor 06/20/17 02:17:48 PM
#6207   MACI Autologous Chondrocyte Implantation Surgical Video - Dr. realfast95 06/13/17 08:30:25 AM
#6206   saw a piece last night on basically taking scubastevemd 06/12/17 04:22:57 PM
#6205   unfriendly short interest realfast95 06/11/17 03:30:11 PM
#6204   The manipulation of VCEL is unbelievable !!! Gremlin3a 06/05/17 10:11:28 AM
#6203   Finally breaking the $3.00 barrier again! lasers 06/01/17 06:25:52 PM
#6202   $3.05 premarket. Fingers crossed. joemont 06/01/17 08:53:05 AM
#6201   From Europe as well as Asia. lasers 05/27/17 01:35:32 PM
#6200   thank yo lasers! and you expect more contracts kei 05/27/17 10:55:35 AM
#6199 lasers 05/27/17 10:37:52 AM
#6198   what is ICT ? thanks. kei 05/27/17 09:55:30 AM
#6197   Read KITE's and JUNO's PRs., and look at charts. north40000 05/26/17 02:28:52 PM
#6196   Your concern would be ? lasers 05/26/17 02:26:25 PM
#6195   Does ICT have a Car-T therapy that has north40000 05/26/17 02:23:37 PM
#6194   Yes ICT is waiting for China regulators to lasers 05/26/17 01:37:39 PM
#6193   About Innovative Cellular Therapeutics commoncentsinvestor 05/26/17 01:35:02 PM
#6192   China contract to be approved with Innovative Cellular lasers 05/26/17 01:08:59 PM
#6191   I think you better check your numbers. This commoncentsinvestor 05/26/17 12:28:25 PM
#6190   Should be interesting next week. Prelude to joemont 05/26/17 12:06:42 PM
#6189   About time they finally let it start to Lunacy aka John Galt 05/26/17 12:00:53 PM
#6188   low volume lifting. Some MM bear must be realfast95 05/26/17 11:25:32 AM
#6187   Starting to pick up steam. Some more prs silvergun 05/26/17 07:37:50 AM
#6186   "Steady......Hooold.....hoooold......hoooold....hooold! joemont 05/23/17 09:23:06 PM
#6185 joemont 05/22/17 02:21:17 PM
#6184   Very bullish for $VCEL and MACI surgeries. lasers 05/22/17 08:44:49 AM
#6183   Experts come out against arthroscopic knee surgery: commoncentsinvestor 05/19/17 04:03:31 PM
#6182   More such, arranged by premium: north40000 05/16/17 02:20:12 PM
#6181   Yep. Look at qcor $3 to over $50 silvergun 05/16/17 09:54:44 AM
#6180   "VCEL has a competitor with better phase 2b results." commoncentsinvestor 05/15/17 02:43:07 PM
#6179   VCEL has a competitor with better phase 2b MicroKing 05/14/17 08:38:30 PM
#6178   "It's funny that ixmyelocel-T went from a dormant commoncentsinvestor 05/14/17 07:14:39 PM
#6177   I have been following it for years. Many lasers 05/12/17 10:30:32 AM
#6176   It's funny that ixmyelocel-T went from a realfast95 05/12/17 10:27:56 AM
#6175   ixmyelocel-T is now part of the licensing program lasers 05/12/17 10:17:37 AM
#6174   On May 10th, 2017, Vericel(VCEL) announced that the lasers 05/12/17 09:38:39 AM
#6173   "upfront payment, EQUITY INVESTMENT, and milestone payments" $1mil me33 05/11/17 06:47:07 PM
#6172   CEO is referring to monies recognition from lasers 05/11/17 10:52:23 AM
#6171   Below is from the Earnings Call Transcript. It's me33 05/11/17 10:34:56 AM
#6170   That has nothing to do with the ICT lasers 05/11/17 10:05:19 AM
#6169   Read Q&A transcript. CEO clarified this. Vericel will me33 05/11/17 07:44:39 AM
#6168   Best read again. lasers 05/11/17 07:09:22 AM
#6167   $6mil upfront is $1mil cash and the rest me33 05/10/17 05:18:54 PM
#6166   Yes, that is what I ment to say. too simple 05/10/17 01:38:08 PM
#6165   Q1 earnings transcript is available realfast95 05/10/17 01:16:12 PM
#6164   they got RMAT today!!!! Chicagojosh 05/10/17 12:13:35 PM
#6163   No actually as ALL of the monies go lasers 05/10/17 10:23:39 AM
#6162   Thanks Lasers, so basically just another form of too simple 05/10/17 10:17:20 AM
#6161   too simple lasers 05/10/17 10:03:21 AM